An Evaluation Of Pacira BioSciences Inc (NASDAQ: PCRX) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

PCRX belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Pacira BioSciences Inc is $816.44M. A total of 0.61 million shares were traded on the day, compared to an average of 1.08M shares.

In the most recent transaction, GAUGLER DARYL sold 500 shares of PCRX for 12.86 per share on Sep 13 ’24. After the transaction, the Chief Operating Officer now owns 115,700 company shares. In a previous transaction on Sep 13 ’24, GAUGLER DARYL bought 500 shares at 12.86 per share.

Among the insiders who bought shares, BIGAL MARCELO acquired of 1,512 shares on Aug 16 ’24 at a per-share price of $13.25. This resulted in the Director holding 10,142 shares of PCRX after the transaction. In another insider transaction, Brege Laura bought 1,000 shares at $12.81 per share on Aug 16 ’24. Company shares held by the Director now total 17,552.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, PCRX has a high of $35.95 and a low of $11.16.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. PCRX’s latest balance sheet shows that the firm has $656.41M in Cash & Short Term Investments as of fiscal 2021. There were $1.13B in debt and $521.12M in liabilities at the time. Its Book Value Per Share was $16.24, while its Total Shareholder’s Equity was $730.41M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCRX is Buy with a score of 3.11.

Most Popular

Related Posts